These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 24439671)

  • 1. Regulation and expression of aberrant methylation on irinotecan metabolic genes CES2, UGT1A1 and GUSB in the in-vitro cultured colorectal cancer cells.
    Xie FW; Peng YH; Chen X; Chen X; Li J; Yu ZY; Wang WW; Ouyang XN
    Biomed Pharmacother; 2014 Feb; 68(1):31-7. PubMed ID: 24439671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between the expression of CES2, UGT1A1, and GUSB in colorectal cancer tissues and aberrant methylation.
    Xie FW; Peng Y; Chen X; Chen X; Li J; Wang W; Yu Z; Ouyang X
    Neoplasma; 2014; 61(1):99-109. PubMed ID: 24195516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of UGT1A1 gene methylation level in colorectal cancer cells on the sensitivity of the chemotherapy drug CPT-11.
    Xie FW; Peng YH; Wang WW; Chen X; Chen X; Li J; Yu ZY; Ouyang XN
    Biomed Pharmacother; 2014 Sep; 68(7):825-31. PubMed ID: 25260839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer.
    Gagnon JF; Bernard O; Villeneuve L; Têtu B; Guillemette C
    Clin Cancer Res; 2006 Mar; 12(6):1850-8. PubMed ID: 16551870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of CES2 RNA expression in neuroblastoma.
    Uchida K; Otake K; Tanaka K; Hashimoto K; Saigusa S; Matsushita K; Koike Y; Inoue M; Ueeda M; Okugawa Y; Inoue Y; Mohri Y; Kusunoki M
    J Pediatr Surg; 2013 Mar; 48(3):502-9. PubMed ID: 23480903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
    Cecchin E; Corona G; Masier S; Biason P; Cattarossi G; Frustaci S; Buonadonna A; Colussi A; Toffoli G
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6901-7. PubMed ID: 16203781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene.
    Bellott R; Le Morvan V; Charasson V; Laurand A; Colotte M; Zanger UM; Klein K; Smith D; Bonnet J; Robert J
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):481-8. PubMed ID: 17483951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
    Schulz C; Boeck S; Heinemann V; Stemmler HJ
    Anticancer Drugs; 2009 Nov; 20(10):867-79. PubMed ID: 19770637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CpG island methylation of BNIP3 predicts resistance against S-1/CPT-11 combined therapy in colorectal cancer patients.
    Hiraki M; Kitajima Y; Nakafusa Y; Nakamura J; Hashiguchi K; Sumi K; Noshiro H; Miyazaki K
    Oncol Rep; 2010 Jan; 23(1):191-7. PubMed ID: 19956881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice.
    Ahowesso C; Piccolo E; Li XM; Dulong S; Hossard V; La Sorda R; Filipski E; Tinari N; Delaunay F; Iacobelli S; Lévi F
    Toxicol Lett; 2010 Feb; 192(3):395-401. PubMed ID: 19931604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan.
    Côté JF; Kirzin S; Kramar A; Mosnier JF; Diebold MD; Soubeyran I; Thirouard AS; Selves J; Laurent-Puig P; Ychou M
    Clin Cancer Res; 2007 Jun; 13(11):3269-75. PubMed ID: 17510208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Relationship between
    Ishimine M; Lee HC; Nakaoka H; Orita H; Kobayashi T; Mizuguchi K; Endo M; Inoue I; Sato K; Yokomizo T
    Dis Markers; 2018; 2018():5280736. PubMed ID: 29651325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of combined therapy with low-dose 5-aza-2'-deoxycytidine and irinotecan on colon cancer cell line HCT-15.
    Ishiguro M; Iida S; Uetake H; Morita S; Makino H; Kato K; Takagi Y; Enomoto M; Sugihara K
    Ann Surg Oncol; 2007 May; 14(5):1752-62. PubMed ID: 17195906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients.
    Rouits E; Charasson V; Pétain A; Boisdron-Celle M; Delord JP; Fonck M; Laurand A; Poirier AL; Morel A; Chatelut E; Robert J; Gamelin E
    Br J Cancer; 2008 Oct; 99(8):1239-45. PubMed ID: 18797458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma.
    Liu CY; Chen PM; Chiou TJ; Liu JH; Lin JK; Lin TC; Chen WS; Jiang JK; Wang HS; Wang WS
    Cancer; 2008 May; 112(9):1932-40. PubMed ID: 18300238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
    Fakih MG; Ross ME; Starostik P
    Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells.
    Bélanger AS; Tojcic J; Harvey M; Guillemette C
    BMC Mol Biol; 2010 Jan; 11():9. PubMed ID: 20096102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
    Innocenti F; Ratain MJ
    Oncology (Williston Park); 2003 May; 17(5 Suppl 5):52-5. PubMed ID: 12800608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Two cases of advanced colorectal cancer with UGT1A1*28 homozygosity treated by FOLFIRI].
    Yokoyama S; Imamura Y; Hatano N; Fukuoka T; Usui H; Morita Y
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1159-61. PubMed ID: 19620808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression and characterization of a human carboxylesterase 2 splice variant.
    Schiel MA; Green SL; Davis WI; Sanghani PC; Bosron WF; Sanghani SP
    J Pharmacol Exp Ther; 2007 Oct; 323(1):94-101. PubMed ID: 17636009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.